ProKidney (NASDAQ:PROK – Get Free Report) and TG Therapeutics (NASDAQ:TGTX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Volatility and Risk
ProKidney has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
Profitability
This table compares ProKidney and TG Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -10,288.39% | N/A | -27.39% |
| TG Therapeutics | 55.22% | 73.49% | 34.14% |
Analyst Ratings
This is a summary of current ratings for ProKidney and TG Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
ProKidney currently has a consensus price target of $10.00, indicating a potential upside of 769.57%. TG Therapeutics has a consensus price target of $63.00, indicating a potential downside of 0.60%. Given ProKidney’s higher possible upside, equities analysts plainly believe ProKidney is more favorable than TG Therapeutics.
Valuation and Earnings
This table compares ProKidney and TG Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $890,000.00 | 390.64 | -$68.99 million | ($0.55) | -2.09 |
| TG Therapeutics | $616.29 million | 15.74 | $447.18 million | $2.74 | 23.13 |
TG Therapeutics has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
TG Therapeutics beats ProKidney on 9 of the 13 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
